The Company’s portfolio of products consists of vaccines against the hepatitis A, hepatitis B and influenza viruses. Its Panflu vaccine is available in China against the H5N1 influenza virus. Its pipeline consists of vaccine candidates in the pre-clinical and clinical development phases in China, including human vaccines for the EV71, Japanese encephalitis and rabies in pre-clinical development, a vaccine for the severe acute respiratory syndrome (SARS) virus that has completed a Phase I clinical trial and a split viron vaccine for the H5N1 influenza virus that has completed a Phase II clinical trial.

Sinovac Biotech Ltd. was the first company in the world to successfully complete clinical trials for an H1N1 vaccine.

It was also the first company approved by the Chinese government to produce millions of doses for the public. China is set to become the first country to begin mass inoculations sometime around the beginning of October.

Sinovac was the first and only company ever to create a vaccine for Severe Acute Respiratory Syndrome (SARS), the worldwide pandemic that left almost 350 people in China dead. The SARS vaccine was never used. By the time it was discovered, the outbreak had subsided. However, the breakthrough has enabled Sinovac to stay ahead of the curve.